Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy

In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents, including recently approved gene therapies. There are several ongoing trials evaluating the safety of these agents in patients, with promising results being demonstrated.

In this podcast, leading experts Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, and Josu de la Fuente, PhD, FRCP, FRCPI, FRCPCH, FRCPath, Imperial College London, London, UK, discuss key updates in SCD presented at the 2023 ASH Annual Meeting and Exposition. The experts cover several topics, including the pathogenesis of SCD, novel agents being explored, and the growing role of gene therapies.

The post Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy appeared first on VJHemOnc.